Concussion Management: Return-to-Play Protocols and Persistent Symptoms
Acute Assessment and Diagnosis
The Sport Concussion Assessment Tool 6 (SCAT6), updated with the 2023 Amsterdam Consensus Statement, provides standardized sideline and office-based evaluation. Diagnosis is clinical, based on a mechanism of injury capable of transmitting force to the brain plus one or more of: symptoms (headache, dizziness, confusion, feeling in a fog), physical signs (loss of consciousness in 10%, amnesia in 25%, balance disturbance), cognitive impairment, or behavioral changes. No single biomarker or imaging modality confirms concussion. Head CT is indicated only for structural injury concerns per the Canadian CT Head Rule (GCS below 15 at 2 hours, suspected skull fracture, 2 or more episodes of vomiting, age above 65). Blood biomarkers (GFAP and UCH-L1) are FDA-cleared to aid in CT decision-making, with a sensitivity of 97.6% and NPV of 99.6% for intracranial lesions on CT.
Initial Management: Active Recovery
The Amsterdam Consensus marks a paradigm shift from strict cognitive and physical rest to active recovery. The 2019 RCT by Leddy et al. demonstrated that early aerobic exercise (sub-symptom threshold, starting within 48 hours) reduced median recovery time from 17 to 13 days compared to stretching control (p=0.009). Current recommendations include 24-48 hours of relative rest followed by gradual introduction of light aerobic exercise (walking, stationary cycling at 50-60% maximum heart rate) that does not exacerbate symptoms. Screen time restriction beyond the first 48 hours is no longer recommended. Return to school with accommodations (reduced workload, exam deferrals, screen breaks) should begin as tolerated, typically within 2-3 days.
Graduated Return-to-Play Protocol
The 6-stage graduated return-to-play protocol requires minimum 24 hours at each stage before advancing: Stage 1 (symptom-limited activity), Stage 2 (light aerobic exercise, 70% max HR), Stage 3 (sport-specific exercise, no head impact), Stage 4 (non-contact training drills, progressive resistance), Stage 5 (full-contact practice after medical clearance), Stage 6 (return to competition). Each stage requires symptom tolerance for 24 hours before progression. Minimum timeline is 7 days from symptom resolution to full return. For children and adolescents, a more conservative approach is recommended: minimum 14 days from symptom resolution based on evidence of prolonged recovery (median 28 days versus 14 days in adults) from the 5P study and PERC 5P validation cohort.
Sponsored
Persistent Post-Concussion Symptoms
Approximately 15-30% of concussed individuals experience persistent symptoms beyond 4 weeks (previously termed post-concussion syndrome). Risk factors include female sex (OR 1.7), prior concussion history, pre-existing migraine or mood disorders, and early high symptom burden (PCSS score above 40 at initial evaluation). Cervicogenic headache and vestibulo-ocular dysfunction are treatable drivers of persistent symptoms and should be specifically evaluated. The Buffalo Concussion Treadmill Test (BCTT) identifies exercise intolerance and guides subsymptom threshold exercise prescription, which has an NNT of 3 for earlier recovery in a randomized controlled trial of persistent symptoms.
Targeted Therapies for Persistent Symptoms
Treatment of persistent symptoms requires a phenotype-directed approach. For post-traumatic headache with migraine features, amitriptyline 10-50 mg at bedtime (NNT 5 at 12 weeks) or topiramate 25-100 mg daily are first-line prophylactics. Vestibular rehabilitation therapy (VRT) improves vestibulo-ocular symptoms in 73% of patients at 8 weeks (Alsalaheen et al. meta-analysis). Cervical spine manual therapy addresses cervicogenic contributions, with an RCT by Schneider et al. showing 73% medical clearance at 8 weeks versus 7% for rest alone. For cognitive symptoms persisting beyond 3 months, neuropsychological testing guides cognitive rehabilitation strategies. CBT for post-concussion anxiety and depression reduces symptom burden (effect size 0.6-0.8). A multimodal clinic model integrating these specialties achieves full recovery in 85% of persistent symptom patients within 12 weeks.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.